$UTHR,...United Therapeutics rallies after favorable court ruling
Shares of United Therapeutics (UTHR +23.1%) jump on 5x surge in volume after a court rules that Sandoz (NVS +0.3%) failed to prove that United's '007 and '117 Remodulin (treprostinil) patents are invalid and that United proved that Sandoz's ANDA will infringe on patent '117.
Remodulin accounted for almost 45% of United's 1H sales of $612.2M.
invest at your own risk, based on your own due diligence, at your own risk tolerance
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.